Expertise in
1
conditions

Jesper A. Johannesen

Copenhagen, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Copenhagen, DK 

Overview

Jesper Johannesen practices practicing medicine in Copenhagen, Denmark.

Mr. Johannesen is highly rated in 1 condition, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Congenital Hyperinsulinism, Low Blood Sugar, and Serum Sickness.

He is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Copenhagen, Denmark
Other Locations
Herlev, Denmark
Gentofte, Denmark
Hellerup, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Recruiting
Publish Date: June 03, 2025
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Study Phase: Phase 2
View 1 Less Clinical Trial

66 Total Publications

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Journal: Lancet (London, England)
Published: July 07, 2025

Frequently Asked Questions about Jesper A. Johannesen

Is Jesper A. Johannesen a top-rated expert for Type 1 Diabetes (T1D)?

MediFind is an objective health platform that identifies experts based on real-world data. Jesper A. Johannesen is classified as an Distinguished expert for Type 1 Diabetes (T1D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jesper A. Johannesen participate in research or clinical trials?

Yes. Jesper A. Johannesen has published 66 articles and abstracts on conditions like Type 1 Diabetes (T1D). You can view a list of Jesper A. Johannesen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Johannesen's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile